A busy Tuesday for small-cap newsflow brought regulatory milestones, contract wins, and a clutch of trading updates reiterating full-year guidance, with Cizzle Biotechnology's US laboratory approval for its CIZ1B lung cancer test among the sharpest catalysts of the session. Everyman Media's admission that Q4 uncertainty clouds an otherwise encouraging first half weighed on its shares, while Gulf Marine Services steadied sentiment by confirming all four evacuated vessels have returned to hire and held its EBITDA guidance firm.
Forgent results signal leaner cost base and execution focus
Forgent (AIM:FORG) published results that chief executive James Parsons described as demonstrating "strong operational momentum," pointing to a leaner cost structure and an enhanced asset portfolio as the foundations for delivery. The shares edged up 5.17% to 0.0183p on the update.
Everyman flags Q4 uncertainty despite 21-week admissions growth
Everyman Media Group (AIM:EMAN) reported admissions, revenue and adjusted EBITDA growth across the 21 weeks to 28 May, and said full-year performance is expected to come in marginally ahead of 2025. However, the independent premium cinema group tempered that outlook by flagging that Q4 trading and planned projects leave the final outcome uncertain, enough to push the shares down 6.03% to 32.89p.
Christie Group enters second half with robust pipeline and in-line outlook
Christie Group (AIM:CTG) used its AGM to deliver a five-month trading update through 31 May, telling shareholders that robust demand and a strengthening pipeline leave the board confident of a full-year outcome in line with expectations. The shares added 1.05% to 144.0p.
Gulf Marine Services holds EBITDA guidance as evacuated vessels return
Gulf Marine Services (AIM:GMS) confirmed that all four vessels temporarily evacuated from a Gulf country have returned to hire on their original contracts, removing a key operational overhang. The company maintained its 2026 adjusted EBITDA guidance of USD 105m-115m, with the shares rising 3.8% to 20.2p.
Active Energy signs GCC distribution deal with Fog Hashing
Active Energy Group (AIM:AEG) announced a distribution agreement with Fog Hashing covering the GCC region, framed by chief executive Paul Elliott as more than a supply deal, emphasising the ability to rapidly deploy, redeploy and upgrade infrastructure as the strategic value. The shares gained 1.85% to 0.0993p.
Cirata embeds Symphony in IBM's Big Replicate under revised deal
Cirata (AIM:CRTA) signed a revised agreement with IBM to embed its Symphony technology within IBM's Big Replicate product, positioning the combined offering as a tool for organisations seeking to accelerate data migration without sacrificing operational continuity. Chief executive Stephen Kelly said the partnership gives clients the capability to drive change while retaining control of trusted data. The shares rose 2.91% to 17.0056p.
SThree reiterates profit guidance on improving first-half trends
SThree (LSE:STEM) reiterated its profit guidance after reporting improving trends in the first half, with chief executive Timo Lehne highlighting that the group's technology investment programme, TIP, is delivering tangible benefits and enabling AI innovation at scale. The shares were broadly flat, slipping 0.24% to 166.4p.
Warpaint London beats early Q2 sales target and holds full-year view
Warpaint London (AIM:W7L) told shareholders at its AGM that early second-quarter sales came in ahead of expectations, and reiterated confidence in its full-year outlook. Executive chairman Clive Garston pointed to significant planned expansion opportunities in the second half of 2026 and continued margin improvement as the key drivers. The shares added 2.33% to 220.0p.
Pri0r1ty Intelligence to deploy SportTower.ai across Sport & Recreation Alliance
Pri0r1ty Intelligence Group (AIM:PR1) announced that its SportTower.ai platform will be rolled out across members of the Sport & Recreation Alliance, marking what chief executive Rory Maxwell described as the first deployment of a scalable, repeatable model. The shares jumped 9.58% to 1.315p on the news.
BSF Enterprise's T-Rex handbag auction delivers commercial validation
BSF Enterprise (AIM:BSFA) reported that its lab-grown leather "T-Rex" handbag, while failing to meet its historic reserve at public auction, delivered the commercial validation the company was seeking for its engineering platform. CEO Dr Che Connon said the outcome "emphatically" confirmed the platform's credentials. The shares rose 8.64% to 1.195p.
Cizzle Biotechnology secures US CLIA approval for CIZ1B lung cancer test
Cizzle Biotechnology Holdings (AIM:CIZ) secured approval from a US CLIA-certified laboratory for its CIZ1B lung cancer detection test, a step founder and CEO Bill Behnke called a pivotal milestone on the path to broader clinical availability in the United States. The shares surged 12.41% to 3.541p, making it one of the session's sharpest movers on substantive news.
Galileo Resources sells Kalahari Copper Belt licences for US$3m plus $80m upside
Galileo Resources (AIM:GLR) agreed to sell Virgo, the vehicle holding two Botswana Kalahari Copper Belt prospecting licences, to a Sandfire unit for US$3m upfront, with a potential future success payment of between $20m and $80m depending on outcomes. The shares gained 2.86% to 0.9p.
Great Southern Copper starts scout drilling at Artemisa South
Great Southern Copper (AIM:GSCU) commenced scout RC drilling at Artemisa South, the fourth and final target in its current porphyry exploration programme, according to chief executive Sam Garrett. Despite the operational progress, the shares fell 5.97% to 2.5201p.
Poolbeg Pharma wins European patent for POLB 001 in cancer immunotherapy complication
Poolbeg Pharma (AIM:POLB) was granted a European patent covering the use of POLB 001 in the prevention of cancer immunotherapy-induced cytokine release syndrome. The company said the award strengthens its IP position ahead of interim data from the TOPICAL trial expected this summer. The shares rose 4.0% to 7.904p.
TPXimpact sets double-digit revenue growth target after completing turnaround
TPXimpact Holdings (AIM:TPX) set a double-digit revenue growth target as it declared its turnaround substantially complete, with chief executive Bjorn Conway saying the business enters FY27 with a strong foundation, disciplined execution, and a client-centred account plan. The shares climbed 7.48% to 66.1p.
Smarter Web Company appoints Oliver Hewett as chief financial officer
Smarter Web Company (AIM:SWC) promoted Oliver Hewett to chief financial officer, with CEO Andrew Webley citing his institutional finance background, hands-on CFO track record, and personal Bitcoin conviction as the combination that made him the right appointment. The shares were essentially unchanged at 29.934p, down 0.22%.
IG Design Group delivers £16.2m cash inflow as simplification pays off
IG Design Group (AIM:IGR) reported a £16.2m cash inflow for the period, with interim executive chair Stewart Gilliland saying the business had delivered on its promise as a "simplified more stable business." The shares added 3.41% to 91.0p.
US Solar Fund grants 90-day exclusivity over potential full portfolio sale
US Solar Fund (LSE:USFP) granted a prospective buyer 90 days of exclusivity to explore a potential sale of its entire portfolio, with chair Gill Nott noting that sustained improved portfolio performance could eventually support a dividend restart. The shares were quoted at 26.9p.
Accsys doubles adjusted EBITDA to €21.2m as FOCUS strategy gains traction
Accsys Technologies (AIM:AXS) reported adjusted EBITDA of €21.2m, double the prior period, as margin approached the Phase I target set out in its FOCUS strategy. CEO Dr Jelena Arsic said the company is delivering on its commitments while driving further sustainable improvements in profitability. The shares rose 1.73% to 78.3286p.
Optima Health confirms FY26 revenue on track as strategic momentum builds
Optima Health (AIM:OPT) said full-year revenue is expected to be in line with expectations, with chief executive Jonathan Thomas pointing to building momentum as the company executes against its strategic objectives. The shares dipped 1.47% to 191.15p.
Istesso enters Phase 2 with leramistat in muscle-wasting disease sarcopenia
IP Group (LSE:IPO) portfolio company Istesso started a Phase 2 clinical trial of leramistat in sarcopenia, a muscle-wasting condition, marking what IP Group chief executive Greg Smith described as an important inflection point for a genuinely novel approach to regenerative medicine. IP Group shares eased 1.05% to 65.8p.
Inspiration Healthcare posts 24% revenue rise on SLE ventilation surge
Inspiration Healthcare Group (AIM:IHC) reported a 24% rise in revenue, driven by strong demand for its SLE neonatal ventilation products. Chief executive Raffi Stepanian said the group is positioned to scale through three core platforms and strengthen its global leadership in neonatal medtech. The shares gained 5.58% to 27.45p.
Gelion takes exclusive global licence to Max-Planck sulfur battery IP
Gelion (AIM:GELN) secured an exclusive global licence to sulfur battery intellectual property developed at the Max-Planck Institute, a deal the company said reflects the technology having more than met expectations during evaluation and positions Gelion to advance materials testing toward commercial collaboration. The shares slipped 1.35% to 18.25p.
Debenhams Group targets double-digit earnings improvement in FY27
Debenhams Group (LSE:DEBS) guided for a double-digit earnings improvement in FY27, with chief executive Dan Finley saying the most significant restructuring phases are substantially complete and exceptional costs are expected to reduce materially, making FY27 the year of further profit growth and sustained free cash flow generation. The shares fell 3.2% to 24.2p.
